OneMedNet (NASDAQ:ONMD) vs. Charles River Laboratories International (NYSE:CRL) Head-To-Head Analysis

Charles River Laboratories International (NYSE:CRL) and OneMedNet (NASDAQ:ONMD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Charles River Laboratories International and OneMedNet, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	0	4	7	0	2.64
OneMedNet	0	0	0	0	N/A

Charles River Laboratories International currently has a consensus target price of $253.23, suggesting a potential upside of 8.89%. Given Charles River Laboratories International’s higher possible upside, research analysts plainly believe Charles River Laboratories International is more favorable than OneMedNet.

Profitability

This table compares Charles River Laboratories International and OneMedNet’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	11.49%	16.53%	7.02%
OneMedNet	N/A	N/A	-116.74%

Volatility & Risk

Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, OneMedNet has a beta of -0.55, suggesting that its stock price is 155% less volatile than the S&P 500.

Valuation and Earnings

This table compares Charles River Laboratories International and OneMedNet’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.13 billion	2.90	$474.62 million	$9.21	25.25
OneMedNet	$1.02 million	14.29	-$23.20 million	($0.19)	-3.22

Charles River Laboratories International has higher revenue and earnings than OneMedNet. OneMedNet is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 1.0% of OneMedNet shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by insiders. Comparatively, 45.7% of OneMedNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Charles River Laboratories International beats OneMedNet on 11 of the 13 factors compared between the two stocks.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

About OneMedNet

OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. The company is based in Eden Prairie, Minnesota.